explore -WSS

explore

author：knowledge 2025-09-30 05:49:56 - browse：2

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Use doctors trained outside the U.S. to ease the physician shortage

leisure time

WSS

Lupron, used to halt puberty in children, may cause lasting health problems

Medicare innovation center doesn’t save money, experts say

AstraZeneca lung cancer study comes in below expectations

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Lawsuit highlights wrinkle for disputes over surprise medical bills

Will an HIV vaccine ever be a reality?

Wikipedia

explore

explore

Sports medicine is finally prioritizing gender equality

Stop Congress from blocking public access to science

Drug repurposing or repositioning? The language matters

The biotech scorecard for Q4: 16 stock

What does generative AI mean for health care? We asked experts

AstraZeneca lung cancer study comes in below expectations

Heart attack and stroke risk calculators need revising

Security flaws in third

Cancer drug shortages should be causing more outrage

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

knowledge

What will Novo Nordisk's VC do with its influx of cash?

Canadians with cystic fibrosis outlive Americans by a decade

Nobel honors Karikó and Weissman's enduring partnership

What we owe ALS patients — and why one company fell short

The United States is paying nearly triple for new Covid vaccines

The United States is paying nearly triple for new Covid vaccines

focus

focus

leisure time

entertainment